Login / Signup

Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.

Keiichi AkahoshiDaisuke BanRyo KubokiAtsushi ObaHiroaki OnoYusuke MitsunoriAtsushi KudoShinji TanakaMinoru Tanabe
Published in: Journal of gastroenterology and hepatology (2018)
Cholangiocarcinoma patients with high OPRT expression would benefit from postoperative adjuvant S-1 therapy, which increases the DFS. Assessment of OPRT expression may contribute to the optimization of adjuvant chemotherapy for cholangiocarcinoma.
Keyphrases
  • poor prognosis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • binding protein
  • patients undergoing
  • prognostic factors
  • patient reported
  • replacement therapy